Conference Coverage

Dual-targeted CAR T shows ‘clinical signal’ in NHL


 

REPORTING FROM TCT 2019

– A dual-targeted, locally manufactured, anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was safe and produced ongoing complete responses in a phase 1 study of heavily pretreated non-Hodgkin lymphoma patients, an investigator reported.

Dr. Parameswaran Hari, Medical College of Wisconsin, Milwaukee Andrew D. Bowser/MDedge News

Dr. Parameswaran Hari

The bispecific CAR T-cell product, designed to limit relapses due to loss of target antigen, was produced at the point of care with a 100% success rate for these heavily pretreated patients, the first of whom has now maintained a complete response for 19 months, said Parameswaran Hari, MD, of the Medical College of Wisconsin, Milwaukee.


“So far, this trial has demonstrated safety for this bispecific vector and suggests a clinical signal, with 7 out of 12 patients with ongoing CR, and with minimal toxicity,” Dr. Hari said at the Transplantation & Cellular Therapy Meetings.

“Point of care delivery, we think, allowed patients to have fresh infusion of CAR T cells, with the avoidance of cryopreservation,” added Dr. Hari, who presented the results on behalf of coinvestigators at the Medical College of Wisconsin and Lentigen Technology.

There was no grade 3 or 4 neurotoxicity or cytokine release syndrome among the 12 patients reported to date in the phase 1, dose-escalation trial, and no patient required intensive care, according to Dr. Hari. Grade 1 and 2 neurotoxicity occurred in two and one patients, respectively, while grade 1 and 2 cytokine release syndrome was observed in three patients each.

Among the 12 patients treated to date, the overall response rate was 81% at day 28, Dr. Hari said, noting that of 6 patients treated at the goal dose of 2.5 x 106 cells/kg, 5 remain in ongoing complete remission.

Pages

Recommended Reading

Daratumumab disappoints in non-Hodgkin lymphoma trial
MDedge Hematology and Oncology
Ibrutinib-MTX-rituximab combo shows promise in CNS lymphoma
MDedge Hematology and Oncology
Anthracyclines, bendamustine are options for grade 3A follicular lymphoma
MDedge Hematology and Oncology
Targeted triplet shows potential for B-cell cancers
MDedge Hematology and Oncology
Few DLBCL patients benefit from nivolumab
MDedge Hematology and Oncology
Adding palbociclib upped responses in previously treated MCL
MDedge Hematology and Oncology
CAR T-cell therapies difficult to compare
MDedge Hematology and Oncology
Researchers characterize new subtype of high-grade DLBCL
MDedge Hematology and Oncology
FDA grants priority review to polatuzumab vedotin for DLBCL
MDedge Hematology and Oncology
Haplo-HCT shows viability in DLBCL
MDedge Hematology and Oncology